



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Answering Reviewers

Reviewer 1:

In this retrospective study, 82 participants with advanced colon cancer was included, 43 patients treated with classical FOLFOX chemotherapy regimen and 39 patients treated with olaparib combined with bevacizumab. They investigated the short-term efficacy, time to progression, safety and their effects on serum parameters of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. Olaparib combined with bevacizumab in the treatment of patients with advanced colorectal cancer has a significant clinical effect, can significantly delay the disease, reduce serum VEGF, MMP-9, COX-2 levels and tumor markers HE4, CA125, CA199 levels, safe and reliable. I have no objections as far as methods are concern. This topic is actual and well described. The manuscript is well written and very interesting, and authors presented also the limitations of the study.

Response: Thanks for your positive comments.

Reviewer 2:

The manuscript deals with an interesting and important point, the authors investigate the olaparib combined with bevacizumab in advanced CRC. The topic has a clinical relevance since the effect of olaparib combined with bevacizumab in the clinical treatment of patients with advanced colon cancer is still unclear. The manuscript is well written: the title reflects the main subject of the article, abstract and keywords well summarize the arguments. The methodology is described in detail and is well structured. The authors retrospectively compared short-term efficacy, TTP, incidence of adverse reactions, serum-related parameters and tumor markers levels in 82 patients with advanced colorectal cancer. The discussion is well articulated according to results and the authors have clearly underlined the limitations and drawbacks of the manuscript. I



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

think one of the advantages of this article is that it provides more ideas for targeted therapy of advanced rectal cancer. The tables are representatives and of good quality.

Response: Thanks for your positive comments.

Reviewer 3:

This study is well examined and the design is also great. The problem is that retrospective studies have limited support for the conclusion, and randomized controlled studies with hypothesis testing may be more clinically meaningful for patients with advanced colorectal cancer treated with Olaparib plus bevacizumab. However, this retrospective study provides more ideas for targeted therapy of advanced rectal cancer, which is worthy of clinical reference. Thanks for sharing such an interesting manuscript.

Response: Thanks for your positive comments.

Editor:

I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastrointestinal Surgery, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original' , the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2023. Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content.

Response: Thank you for your suggestions. We have prepared and arranged the Figure 1 using PowerPoint, and it was original. We marked the "Copyright ©The Author(s) 2023" in the PPT file. Also, we provided the standard three-line tables in separate Word document.